LEVELS OF ANTI-B13 ANTIBODIES OVER TIME IN A COHORT OF CHRONIC INFECTED BY TRYPANOSOMA CRUZI. ITS RELATIONSHIP WITH SPECIFIC TREATMENT AND CLINICAL STATUS

OLIVERA, VERÓNICA; BIZAI, MARIA L.; ARIAS, EVELYN; SUASNABAR, SANTIAGO; BOTTASSO, OSCAR; MARCIPAR, IVAN; FABBRO, DIANA

ACTA TROPICA

ELSEVIER SCIENCE BV

Año: 2021 p. 1 - 6

0001-706X

The immunodominant B13 protein of Trypanosoma cruzi is found on the surface of trypomastigotes and exhibits cross-reactivity with the human cardiac myosin heavy chain; for which antibodies against this parasitic antigen may be involved in the development of disease pathology.In a cohort of chronically T. cruzi-infected adults, undergoing trypanocidal treatment, or not, we, therefore, decided to evaluate the levels of anti-B13 antibodies (ELISA-B13) and its eventual relationship with heart complaints. Two hundred twenty-eight serum samples from 76 chronically infected adults with an average follow-up of 24 years were analyzed. Thirty of them had received trypanocidal treatment. Among treated patients, anti-B13 Ab levels in successive samples showed a significant decrease in reactivity as the years after treatment increased (ANOVA test, p = 0.0049). At the end of the follow-up, 36.7% became non-reactive for ELISA B13. Untreated patients did not have significant variations in the level of anti-B13 antibodies during follow-up. None of the treated patients had electrocardiographic changes compatible with chronic chagasic cardiomyopathy,whereas 21.7% of those undergoing no treatment did show such kind of pathological electrocardiogram tracings. ELISA-B13 was reactive in all cases with heart involvement. Among untreated patients, there were no significant differences in anti-B13 antibodies when comparing individuals without proven pathology with those with chronic chagasic cardiomyopathy.Although treatment with trypanocidal drugs was followed by decreased anti-B13 antibody levels, such assessment was unhelpful in differentiating the evolution of chronic chagasic heart disease.